

SEQUENCE LISTING

<110> AstraZeneca AB

<120> METHODS AND COMBINATIONS FOR THE TREATMENT OF CANCER USING IMMUNE CHECKPOINT INHIBITOR ANTIBODIES

<130> P69728W0

<140> US 63/023,554

<141> 2019-05-12

<160> 16

<170> PatentIn version 3.5

<210> 1

<211> 108

<212> PRT

<213> Artificial Sequence

<220>

<223> light chain variable region

<400> 1

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser
20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45

Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro
85 90 95

Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105

<210> 2
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> heavy chain variable region

<400> 2

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr
20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu Ala Phe Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 3
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> HC-CDR1

<400> 3

Gly Phe Thr Phe Ser Arg Tyr Trp Met Ser
1 5 10

<210> 4
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> HC-CDR2

<400> 4

Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys
1 5 10 15

Gly

<210> 5
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> HC-CDR3

<400> 5

Glu Gly Gly Trp Phe Gly Glu Leu Ala Phe Asp Tyr
1 5 10

<210> 6
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> LC-CDR1

<400> 6

Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr Leu Ala
1 5 10

<210> 7
<211> 7
<212> PRT
<213> Artificial Sequence

<220>

<223> LC-CDR2

<400> 7

Asp Ala Ser Ser Arg Ala Thr
1 5

<210> 8

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> LC-CDR3

<400> 8

Gln Gln Tyr Gly Ser Leu Pro Trp Thr
1 5

<210> 9

<211> 139

<212> PRT

<213> Artificial Sequence

<220>

<223> light chain variable region

<400> 9

Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys
1 5 10 15

Arg Ala Ser Gln Ser Ile Asn Ser Tyr Leu Asp Trp Tyr Gln Gln Lys
20 25 30

Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln
35 40 45

Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
50 55 60

Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr
65 70 75 80

Cys Gln Gln Tyr Tyr Ser Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys
85 90 95

Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro
100 105 110

Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu
115 120 125

Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val
130 135

<210> 10

<211> 167

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain variable region

<400> 10

Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser
1 5 10 15

Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro
20 25 30

Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn
35 40 45

Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
50 55 60

Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu
65 70 75 80

Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Arg Gly Ala Thr Leu
85 90 95

Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val
100 105 110

Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala
115 120 125

Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu
130 135 140

Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
145 150 155 160

Ala Leu Thr Ser Gly Val His
165

<210> 11
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> HC-CDR1

<400> 11

Gly Phe Thr Phe Ser Ser Tyr Gly Met His
1 5 10

<210> 12
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> HC-CDR2

<400> 12

Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
1 5 10 15

<210> 13
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> HC-CDR3

<400> 13

Asp Pro Arg Gly Ala Thr Leu Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val
1 5 10 15

<210> 14
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> LC-CDR1

<400> 14

Arg Ala Ser Gln Ser Ile Asn Ser Tyr Leu Asp
1 5 10

<210> 15
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> LC-CDR2

<400> 15

Ala Ala Ser Ser Leu Gln Ser
1 5

<210> 16
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> LC-CDR3

<400> 16

Gln Gln Tyr Tyr Ser Thr Pro Phe Thr
1 5